Affinity vs. Tumor Penetration: Finding the Right ADC Balance
For an antibody-drug conjugate (ADC), the strongest possible target binding is not automatically the best choice. High affinity can support target capture, but in some solid tumors it may also cause an ADC to bind and internalize near blood vessels before it reaches cells deeper in the tumor. The practical goal is to select a binding profile that delivers enough target engagement across the tumor, while preserving internalization, payload delivery, and acceptable exposure in healthy tissues. We recommend evaluating affinity alongside penetration and functional data—not treating affinity as a standalone ranking score.
For more information, please visit our website.
What the Affinity–Penetration Trade-Off Means
Affinity describes binding; penetration describes distribution
Affinity describes how tightly a molecule binds its target and is commonly reported as a dissociation constant, or KD. A lower KD indicates tighter binding under the conditions of the assay, but does not by itself predict how an ADC will distribute through a solid tumor. Tumor penetration describes how far and how evenly the molecule reaches tumor tissue after leaving the bloodstream.
These properties interact with target abundance, antigen accessibility, internalization rate, tumor architecture, and the ADC’s size and pharmacokinetics. A high-affinity molecule may be captured quickly by cells close to vessels, leaving less available to diffuse farther. This binding-site barrier is a possible design consideration, not a universal outcome: the effect depends on the biology and experimental model.
Why nanobody size changes the discussion
Conventional IgG antibodies have a molecular mass of approximately 150 kDa, while a single-domain VHH nanobody is typically about 12–15 kDa. The smaller binding domain may help tissue access in some contexts, but size alone does not guarantee better tumor coverage. A nanobody-based ADC still needs suitable stability, circulation time, target binding, conjugation, and payload delivery.
Quick Comparison: High Affinity and Greater Penetration
| Design consideration | Higher-affinity binding | Penetration-oriented profile |
|---|---|---|
| Potential advantage | May improve target capture and retention when target engagement is limiting. | May improve access to cells farther from vessels or across heterogeneous tissue. |
| Potential limitation | Rapid binding or internalization near the tumor vasculature may restrict distribution in some models. | Binding that is too weak may reduce target occupancy, retention, or payload delivery. |
| Key variables | Target density, binding kinetics, internalization, and normal-tissue expression. | Molecular format, tumor architecture, exposure, target density, and binding kinetics. |
| Evidence to collect | Binding and internalization assays, followed by functional ADC testing. | Spatial distribution or penetration assays, supported by functional and exposure data. |
The comparison is not simply “strong binding versus weak binding.” For example, a hypothetical pair with KD values of 1 nM and 100 nM differs by 100-fold in that measured affinity, but those numbers alone cannot identify the better ADC candidate. Assay conditions, binding kinetics, antigen presentation, and performance in relevant tumor models all matter. Use such values to describe candidates—not to establish a universal cutoff.
How to Choose the Right Balance
Start with the tumor and target
First, establish where the target is expressed and whether expression varies between tumor regions or among patients. For veterinary applications, confirm target relevance in the intended animal species and tumor type rather than assuming that human data transfer directly. Assess expression in important healthy tissues as well, because target-dependent binding outside the tumor can affect the therapeutic window.
Next, determine whether the target can internalize and traffic in a way that supports delivery of the chosen payload. Strong surface binding is not sufficient if the ADC does not reach the intended intracellular compartment or release an active payload. Conversely, a candidate with less extreme affinity may be worth investigating if it provides broader tissue distribution and adequate functional activity.
Screen candidates across more than one assay
We recommend comparing a panel of binders with different measured affinities, rather than selecting only the tightest binder from an initial screen. Measure binding kinetics and cell-surface binding under relevant conditions, then assess internalization and payload-dependent activity. Where feasible, include three-dimensional tumor models or spatially resolved assays that can reveal distribution patterns hidden by standard cell assays.
Keep the ADC format consistent when comparing candidates. Changes in linker, payload, conjugation site, drug-to-antibody ratio, or molecular format can alter properties beyond affinity, making results difficult to interpret. Include appropriate unconjugated binder and non-targeting controls, and document assay conditions so that apparent differences can be evaluated in context.
For more information, please visit NBbiolab.
Interpret results as a linked evidence package
A useful decision combines target binding, tumor distribution, internalization, cytotoxic function, and exposure. If a high-affinity candidate binds strongly but shows limited distribution in a relevant model, test whether that pattern is associated with target density, rapid internalization, or another feature of the model. If a more penetrant candidate shows weaker activity, determine whether the limitation is inadequate binding, insufficient exposure, or a downstream payload issue.
Do not infer clinical performance from one in vitro result. Models differ in vascular structure, extracellular matrix, target expression, and immune context. Findings should be treated as evidence for prioritizing candidates and designing follow-up studies, not as a guarantee of therapeutic outcome.
Application Considerations for Veterinary ADC Programs
Veterinary development adds a species-specific layer to candidate selection. A binder intended for a canine, feline, equine, or other veterinary target should be assessed against the relevant species’ target sequence and cell biology. Cross-reactivity, target distribution in healthy tissues, and the availability of suitable tumor samples or models can affect which experiments are informative.
For companion-animal oncology, a practical program should connect discovery assays to the intended indication and eventual development plan. Consider whether the target is accessible in the tumor type, whether tissue heterogeneity is likely to matter, and what pharmacology and safety evidence will be needed. These questions can guide whether affinity optimization, penetration-focused screening, or a broader candidate panel deserves priority.
Common Selection Mistakes
- Ranking candidates by KD alone: affinity does not establish penetration, internalization, or ADC potency.
- Assuming smaller means better distributed: nanobody size may be advantageous in some settings, but distribution also depends on binding, exposure, and tumor biology.
- Changing several design variables at once: keep the format and conjugation strategy controlled during comparisons where possible.
- Using an irrelevant model: confirm species and target relevance, particularly in veterinary programs.
- Overinterpreting a single assay: use complementary evidence and state model limitations clearly.
Buyer Guidance and NBbiolab Support
When evaluating an ADC target nanobody discovery partner, ask how candidate selection will connect binding measurements to functional assessment. Clarify the target species, intended indication, sample or model availability, desired molecular format, and the evidence needed at each project stage. Also align early on deliverables, timelines, decision gates, and whether downstream conjugation or characterization is within the project scope.
NBbiolab can discuss discovery strategies for veterinary ADC target nanobodies and help define a candidate-evaluation plan around your target and project requirements. The appropriate scope depends on the available target information, species, assays, and development stage; no affinity value or discovery workflow can guarantee tumor penetration or clinical efficacy. A clear brief helps establish which data are feasible and how candidates should be compared.
Conclusion: Select for Functional Tumor Coverage
The right ADC balance is not the highest affinity or the smallest binder by default. It is the candidate that combines sufficient target engagement with useful tumor distribution, appropriate internalization, and functional payload delivery in relevant models. For veterinary programs, species-specific target validation and healthy-tissue assessment should be part of that decision.
As a next step, define the intended species and tumor indication, then compare a controlled panel of binders using binding, internalization, distribution, and functional assays. NBbiolab welcomes B2B inquiries to discuss an ADC target nanobody discovery scope and the evidence needed to prioritize candidates for your program.